Scientific Publications Scientific Publications A new era of in vivo gene therapy: the applicability of a differentiated HSV-1 based vector platform for redosable medicines | Cell & Gene Therapy Insights Topical Herpesvirus Gene Therapy Enters Final Lap | Nature Biotechnology SID 2022 Presentation – B-VEC – GEM-3 Safety and Immunogenicity SID 2022 – B-VEC – GEM-3 Safety and Immunogenicity In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial | Nature Medicine GEM-3: A Phase 3 Study of Beremagene Geperpavec (B-VEC), an Investigational, Topical Gene Therapy, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) ASDS 2021 – KB303 – In vitro and In vivo preclinical NACFC 2021 – KB407 – Nonclinical Pharmacology Sept 2021 - Marinkovich - BVEC talk for DEBRA Sept 2021 - BVEC - DEBRA Intl Corneal Scratch Model DCC 2021 - Topical Application of Beremagene Geperpavec ASGCT 2021 - KB500s - vectorized antibodies in vitro and in vivo data SID 2021 - B-VEC - GEM-1/2 Safety Review SID 2021 - KB301 - Phase 1 Safety April 2021 - KB105 - Freedman et al. JID publication ASDS 2020 - KB301 - Preclinical (in vitro and in vivo) ASGCT 2020 - KB407 - In Vitro Data SID 2020 - KB105 - Phase 1 Data SID 2020 - B-VEC - Complete GEM-1/2 Data Oct 2019 - B-VEC - GEM-1/2 Update June 2019 - GEM-2 Update SID 2019 - KB105 - Preclinical (in vitro) SID 2019 - KB105 - Preclinical (in vivo) SID 2019 - KB104 - Preclinical IID 2018 - B-VEC - Preclinical (in vivo) EB 2017 - B-VEC - Preclinical (in vitro and in vivo)
A new era of in vivo gene therapy: the applicability of a differentiated HSV-1 based vector platform for redosable medicines | Cell & Gene Therapy Insights
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial | Nature Medicine
GEM-3: A Phase 3 Study of Beremagene Geperpavec (B-VEC), an Investigational, Topical Gene Therapy, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
